

Actotalk In Tabriz

Sept, 2021



Together for a healthy future



Dr Mitra Niafar, MD Professor of Endocrinology & Metabolism Department of Internal Medicine, School of Medicine Endocrine Research Center Tabriz University of Medical Sciences

Case (1)

- 48 y/o woman
- Admitted to the hospital
- CC: Chest pain
- Middle income
- PMHx:
 - ≻Smoker
 - History of gestational diabetes
 - Positive family history of T2DM, MI, and Stroke

- PE: On the day of admission
- ≻BP: 198/101 mmHg
- ≻ HR: 122 bpm
- ≻ Oral temp.: 37.4 °C
- ≻BW: 116 kg
- ≻BH: 167 cm
- **BMI:** 41.4
- Electrocardiogram (-) for MI
- ►(-) cardiac enzymes

Lab test on admission day

Lab Test

HbA1c: 9.5%; Random Blood Glu: 310 mg/dL

Cr: 1.5 mg/dl

LFT: AST: 19 - ALT: 26

TSH : Normal

TG:250 mg/dl , LDL: 141 mg/dl HDL: 22 mg/dl

BUN: 35 mg/dL, U/A Albumin: negative

Blood Glucose Follow-up

- Patient is admitted for a cardiac catheterization and further cardiac work-up. Her blood glucose was controlled by insulin (rapid acting). She stayed for 4 day. On hospital day 3, the patient awakened with a blood glucose level of 248 mg/dL. Her physician initiated basal insulin to obtain better glucose control. Her angiogram showed normal epicardial coronary artery and she was cleared for discharge by her cardiologist, but her primary care physician would prefer to monitor her glucose levels for one more day, including her two-hour postprandial level after her evening meal. Throughout the day, the following blood glucose levels were documented:
 - 7 a.m.: 248 mg/dL
 - 11 a.m.: 121 mg/dL
 - 5 p.m.: 118 mg/dL
 - 7 p.m. (two-hour postprandial): 210 mg/dL
 - 9 p.m.: 178 mg/dL
- The following morning, the patient was discharged to home with prescription on oral antidiabetics.



10-year risk of heart disease or stroke

43.7%

What antidiabetic(s) should be started in the first place?

Which one?

Along side of life style modification (calorie restriction and increasing physical activity):

- 1. Start with Metformin 500 mg BD then add Empagliflozin 10 mg/day or change to Metformin/Empagliflozin (500/5) BD
- 2. Start with Empagliflozin Plus (500/5) BD then increase to Empagliflozin Plus (1000/5) BD
- 3. Start with Empagliflozin plus (500/5) BD then add Sitagliptin 50 mg/day
- 4. Start with Metformin 500 mg BD and Liraglutide
- 5. Start with Metformin 500 mg BD and Liraglutide then add Empagliflozin 10 mg/day
- 6. Start with Glibenclamide 5 mg/day
- 7. Start with Gliclazide MR 30 mg/day then increase the dose or add Metformin
- 8. Other options?


The Status of SGLT2-I in Primary

Prevention of Cardio-renal

Complication


Among Patient With Diabetes

Comorbidities among men (N=10,104) and women (N=20,098) with diabetes



9/14/2021

Diabetes in Iran: Prospective Analysis from First Nationwide Diabetes Report of National Program for Prevention and Control of Diabetes (NPPCD-2016). Sci Rep . 2017 Oct 18;7(1):13461.




Prevalence of chronic vascular complications


9/14/2021

Diabetes in Iran: Prospective Analysis from First Nationwide Diabetes Report of National Program for Prevention and Control of Diabetes (NPPCD-2016). Sci Rep . 2017 Oct 18;7(1):13461.


Diabetes-associated Complication



Physiologic mechanisms implicated in the cardiovascular and renal protection with SGLT2 inhibition




Cardiovascular Outcomes Trials



Study Patients: Eligible patients with type 2 diabetes were adults (\geq 18 years of age) with a BMI 45 or less and an eGFR of at least 30 ml per minute per 1.73 m2 of body-surface area, All the patients had established cardiovascular disease and had a HbA1c of at least 7.0% and no more than 9.0%.


The primary composite outcome was death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke.

Key CV Outcomes from EMPA-REG Outcome



CV, cardiovascular; ECVD, established cardiovascular disease; hHF, hospitalization for heart failure; MACE, major adverse cardiovascular events. Composite renal outcome was progression to macroalbuminuria (urinary albuminto-creatinine ratio>300mg/g); a doubling of the serum creatinine level, accompanied by an estimated glomerular filtration rate of \leq 45mL/min/1.73m²; the initiation of renal-replacement therapy; or death from renal disease.

Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373, 2117–2128 (2015).



METHODS

The CANVAS Program integrated data from two trials involving a total of 10,142 participants with type 2 diabetes and high cardiovascular risk. Participants in each trial were randomly assigned to receive canagliflozin or placebo and were followed for a mean of 188.2 weeks.

The primary outcome was a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke.

Participant


Participants were men and women with type 2 diabetes (HbA1c \geq 7.0% and \leq 10.5%) and were either 30 years of age or older with a history of symptomatic atherosclerotic cardiovascular disease or **50 years** of age or older with two or more of the following risk factors for cardiovascular disease:

- \checkmark duration of diabetes of at least 10 years,
- ✓ SBP higher than 140 mm Hg while they were receiving one or more antihypertensive agents,
- ✓ current smoking,
- ✓ microalbuminuria or macroalbuminuria,
- \checkmark or HDL cholesterol level of less than 38.7 mg per deciliter.

9/14/2021

Canagliflozin and cardiovascular and renal events in type 2 diabetes. N. Engl. J. Med. 377, 644–657 (2017).

Key CV Outcomes from CANVAS Program



CV, cardiovascular; ECVD, established cardiovascular disease; hHF, hospitalization for heart failure; MACE, major adverse cardiovascular events. Composite renal outcome was sustained 40% reduction in the estimated glomerular filtration rate, the need for renal-replacement therapy, or death for renal cases.

Conclusion

In two trials involving patients with type 2 diabetes and an elevated risk of cardiovascular disease, patients treated with canagliflozin had a lower risk of cardiovascular events than those who received placebo but a greater risk of amputation, primarily at the level of the toe or metatarsal (6.3 vs. 3.4 participants per 1000 patient-years; hazard ratio, 1.97; 95% CI, 1.41 to 2.75).

9/14/2021 Canagliflozin and cardiovascular and renal events in type 2 diabetes. N. Engl. J. Med. 377, 644–657 (2017).

Real-World Data, Top of Metformin, SUL vs. DPP4I vs. SGL2-I

SPECIAL FOCUS ISSUE: CARDIOVASCULAR HEALTH PROMOTION

ORIGINAL INVESTIGATIONS

J Am Coll Cardiol. 2018 Jun 5;71(22):2497-2506.

IF: 24.09

SGLT-2 Inhibitors and Cardiovascular Risk An Analysis of CVD-REAL

Matthew A. Cavender, MD, MPH,^{a,b} Anna Norhammar, MD,^c Kåre I. Birkeland, MD,^d Marit Eika Jørgensen, MD,^{e,f} John P. Wilding, MD,^g Kamlesh Khunti, MD,^h Alex Z. Fu, PHD,ⁱ Johan Bodegård, MD,^j Betina T. Blak, PHD,^k Eric Wittbrodt, PHARMD, MPH,¹ Marcus Thuresson, PHD,^m Peter Fenici, MD,ⁿ Niklas Hammar, PHD,^{c,o} Mikhail Kosiborod, MD,^p on behalf of the CVD-REAL Investigators and Study Group

Background: Prior studies found patients treated with sodium-glucose co-transporter-2 inhibitors (SGLT-2i)

had lower rates of death and heart failure (HF). Whether the benefits of SGLT-2i vary based upon the presence of cardiovascular disease (CVD) is unknown.

Objectives: This study sought to determine the association between initiation of SGLT-2i therapy and HF or death in patients with and without CVD.

Methods: The CVD-REAL (Comparative Effectiveness of Cardiovascular Outcomes in New Users of SGLT-2 Inhibitors) study was a multinational, observational study in which adults with type 2 diabetes were identified. Patients prescribed an SGLT-2i or other glucose-lowering drugs (GLDs) were matched based on a propensity sg/ra/2012 initiation of an SGLT-2i. Hazard ratios (HRs) for the risk of death, HF, and HF or death in patients

with and without established CVD were estimated for each country and pooled

CENTRAL ILLUSTRATION Sodium-Glucose Co-Transporter-2 Inhibitors in Patients With and Without Cardiovascular Disease

Death	With prior cardiovascular disease*		⊢∎-1	44	0.56 [0.44, 0.70]
Death	Without prior cardiova	HEH	44	0.56 [0.50, 0.63]	
	With prior cardiovascular disease*		H	28	0.72 [0.63, 0.82]
Heart failure	Without prior cardiovascular disease*		⊢■→	39	0.61 [0.48, 0.78]
	With prior cardiovascular disease*		HH	37	0.63 [0.57, 0.70]
Heart failure+Death	Without prior cardiova	HEH	44	0.56 [0.50, 0.62]	
*Diagnosis of AMI, unstable angina transient ischemic attack, com (CABG or PCI) or occlusive pe prior to index drug initiation	favor sodium-gluco co-transporter-2 in 0.25				
Cavender, M.A. et al. J Am Coll Cardiol. 2018;71(22):2497-506.					
Pooled adjusted hazard ratios from meta-analyses for death, heart failure, and heart failure or death in patients with and without cardiovascular disease at initiation of the index drug in the intention-to-treat cohort. AMI = acute myocardial infarction; CABG = coronary artery bypass graft; PCI = percutaneous coronary intervention.					

9/14/2021

BMJ. 2020 Sep 23;370:m3342.

Sodium glucose cotransporter 2 inhibitors and risk of major adverse cardiovascular events: multi-database retrospective cohort study

Kristian B Filion,^{1,2} Lisa M Lix,³ Oriana HY Yu,^{1,4} Sophie Dell'Aniello,¹ Antonios Douros,^{1,2,5} Baiju R Shah,^{6,7,8} Audray St-Jean,¹ Anat Fisher,⁹ Eric Tremblay,¹⁰ Shawn C Bugden,^{11,12} Silvia Alessi-Severini,^{11,13} Paul E Ronksley,¹⁴ Nianping Hu,¹⁵ Colin R Dormuth,⁹ Pierre Ernst,^{1,2} Samy Suissa,^{1,2} on behalf of the Canadian Network for Observational Drug Effect Studies (CNODES) Investigators

Objective: To compare the risk of cardiovascular events between sodium glucose cotransporter 2 (SGLT2) inhibitors and dipeptidyl peptidase-4 (DPP-4) inhibitors among

people with type 2 diabetes in a real world context of clinical practice.

Design: Multi-database retrospective cohort study using a prevalent new user design with subsequent meta-analysis.

Population: 209 867 new users of a SGLT2 inhibitor matched to 209 867 users of a

DPP-4 inhibitor on time conditional propensity score and followed for a mean of 0.9 9/14/2021 years.

Table 2 | Crude and adjusted hazard ratios for association between sodium glucose cotransporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP-4) inhibitors and risk of cardiovascular outcomes

		Person years	Crude incidence rate per 1000 person years	Crude hazard ratio (95% CI)*	Adjusted models*†	
Cardiovascular outcomes by drug	No of events				Hazard ratio (95% CI)	l ² (%)
MACE:						
SGLT2 inhibitors	2146	188782	11.4	0.72 (0.65 to 0.80)	0.76 (0.69 to 0.84)	47 28%
DPP-4 inhibitors	3001	181733	16.5	1.00 (Reference)	1.00 (Reference)	
Myocardial infarction:						
SGLT2 inhibitors	995	196503	5.1	0.81 (0.72 to 0.92)	0.82 (0.70 to 0.96)	53 19%
DPP-4 inhibitors	1169	182398	6.4	1.00 (Reference)	1.00 (Reference)	
lschaemic stroke:						
SGLT2 inhibitors	501	190047	2.6	0.78 (0.68 to 0.89)	0.85 (0.72 to 1.01)	28
DPP-4 inhibitors	636	182731	3.5	1.00 (Reference)	1.00 (Reference)	
Cardiovascular death:						
SGLT2 inhibitors	738	189276	3.9	0.55 (0.47 to 0.65)	0.60 (0.54 to 0.67)	14 40%
DPP-4 inhibitors	1399	182746	7.7	1.00 (Reference)	1.00 (Reference)	
All cause mortality:						
SGLT2 inhibitors	1651	189278	8.7	0.54 (0.48 to 0.60)	0.60 (0.54 to 0.67)	42 40%
DPP-4 inhibitors	3156	183075	17.3	1.00 (Reference)	1.00 (Reference)	
Heart failure:						
SGLT2 inhibitors	587	189058	3.1	0.40 (0.35 to 0.46)	0.43 (0.37 to 0.51)	43 57%
DPP-4 inhibitors	1401	181956	7.7	1.00 (Reference)	1.00 (Reference)	

MACE=major adverse cardiovascular events.

*Users of SGLT2 inhibitors were matched to users of DPP-4 inhibitors from their exposure set (defined on level of antidiabetic therapy, time on DPP-4 inhibitors for prevalent new users only, prior use of glucagon-like peptide-1 receptor agonists, and within 120 days of the SGLT2 prescription) on time-conditional propensity score.

†Adjusted for age (continuous), sex, diabetes duration (continuous), and 10ths of time conditional propensity score.

Table 3 | Summary results for stratified analyses of pooled adjusted hazard ratios (95% confidence intervals) for major adverse cardiovascular events (MACE) and heart failure associated with use of sodium glucose cotransporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP-4) inhibitors

Subgroup	Adjusted hazard ratio (95% CI)*	l ² (%)	
MACE			
Main analysis	0.76 (0.69 to 0.84)	47	
History of cardiovascular disease†:			
Yes	0.71 (0.59 to 0.86)	67	29%
No	0.78 (0.69 to 0.88)	40	22%
SGLT2 inhibitor molecule:			
Canagliflozin	0.79 (0.66 to 0.94)	67	
Dapagliflozin	0.73 (0.63 to 0.85)	32	
Empagliflozin	0.77 (0.68 to 0.87)	1	
Heart failure			
Main analysis	0.43 (0.37 to 0.51)	43	
History of heart failure§:			
Yes	0.44 (0.35 to 0.55)	33	56%
No	0.47 (0.41 to 0.53)	0	53%
SGLT2 inhibitor molecule:			
Canagliflozin	0.41 (0.32 to 0.52)	42	
Dapagliflozin	0.44 (0.36 to 0.54)	0	
Empagliflozin	0.52 (0.43 to 0.65)	4	

Nova Scotia had zero events in one of the treatment groups and thus was not included in the cardiovascular disease (yes) analysis for MACE or in the age

(≥70 years), sex, history of heart failure, and SGLT2 inhibitor molecule analyses for heart failure.

*Adjusted for age (continuous), sex, diabetes duration (continuous), and 10ths of time conditional propensity score.

†Coronary artery disease, peripheral arterial disease, or cerebrovascular disease in the past three years.

‡Prescription for insulin in past year.

§Two outpatient codes or one inpatient code in the past three years.

JAMA Internal Medicine | Original Investigation IF: 21.87

Comparative Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors vs Sulfonylureas in Patients With Type 2 Diabetes

Yan Xie, MPH; Benjamin Bowe, MPH; Andrew K. Gibson, MPH; Janet B. McGill, MD; Geetha Maddukuri, MD; Ziyad Al-Aly, MD


Importance: In the treatment of type 2 diabetes, evidence of the comparative effectiveness of sodiumglucose cotransporter 2 (SGLT2) inhibitors vs sulfonylureas-the second most widely used antihyperglycemic class after metformin-is lacking. **Objective:** To evaluate the comparative effectiveness of SGLT2 inhibitors and sulfonylureas associated with the risk of all-cause mortality among patients with type 2 diabetes using metformin. Design, setting, and participants: A cohort study used data from the US Department of Veterans Affairs compared the use of SGLT2 inhibitors vs sulfonylureas in individuals receiving metformin for treatment of type 2 diabetes. A total of 23 870 individuals with new use of SGLT2 inhibitors and 104 423 individuals with new use of sulfonylureas were enrolled between October 1, 2016, and February 29, 2020, and followed up until January 31, 2021.

Exposures: New use of SGLT2 inhibitors or sulfonylureas.

9/14/2021

Main outcomes and measures: This study examined the outcome of all-cause mortality.

2021 Jun 28;e212488.



9/14/2021


Comparative Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors vs Sulfonylureas in Patients With Type 2 Diabetes.

Figure 2. Intention-to-Treat Hazard Ratios (HRs) and Event Rate Reduction for All-Cause Mortality in the Overall Cohort and Prespecified Subgroups

	Analyses	Event reduction per 1000 person-years (95% CI)	HR (95% CI)	F	avors SGLT2 inhibitors	Favors sulfonylureas
	Overall	-5.15 (-7.16 to -3.02)	0.81 (0.75-0.87)		—	
	Age, y					
	≤65	-2.17 (-4.32 to -0.29)	0.85 (0.73-0.99)			
	>65	-7.05 (-9.71 to -3.99)	0.81 (0.74-0.88)		—	
	CVD					
	No	-4.95 (-6.90 to -3.31)	0.81 (0.75-0.88)		—	29%
	Yes	-3.59 (-6.14 to -0.89)	0.85 (0.75-0.97)			15%
	eGFR, mL/min/1.73 m ²					
	≥90	-3.74 (-6.20 to -0.68)	0.79 (0.67-0.94)	_		
	≥60 to <90	-3.51 (-6.19 to -0.99)	0.86 (0.78-0.96)			
	≥45 to <60	-9.18 (-13.53 to -2.91)	0.78 (0.66-0.91)			
>	≥30 to >45	-18.27 (-33.34 to -1.10)	0.71 (0.50-1.00)			
	Albuminuria status ^a					
	No albuminuria	-2.71 (-4.69 to -0.79)	0.88 (0.79-0.98)			
	Microalbuminuria	-6.69 (-10.02 to -3.48)	0.79 (0.70-0.89)			
	Macroalbuminuria	-14.70 (-23.04 to -5.97)	0.68 (0.53-0.85)		-	
	BMI					
	>18.5 to ≤25	-17.40 (-28.04 to -7.58)	0.69 (0.54-0.87)	-	—	
	>25 to ≤30	-4.64 (-7.80 to -1.15)	0.84 (0.73-0.97)			
	>30	-3.73 (-5.56 to -1.95)	0.84 (0.77-0.92)		I	
			0.	5 0.75 HR (95% CI)	1	

Comparative Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors vs Sulfonylureas in Patients With Type 2 Diabetes.

Figure 3. Per-Protocol Hazard Ratios (HRs) and Event Rate Reduction for All-Cause Mortality



Hazard ratios of all-cause mortality in continued use of sodium-glucose cotransporter 2 (SGLT2) inhibitors or sulfonylureas (reference group) throughout follow-up (top graph) and continued use of SGLT2 inhibitors with metformin or SGLT2 inhibitors without metformin (reference group) throughout follow up (bottom graph)


9/14/2021

Conclusion

In this comparative effectiveness study analyzing data from the US Department of Veterans Affairs, among patients with type 2 diabetes receiving metformin therapy, SGLT2 inhibitor treatment was associated with a reduced risk of all-cause mortality compared with sulfonylureas. The results provide data from a real-world setting that might help guide the choice of antihyperglycemic therapy.

9/14/2021 Comparative Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors vs Sulfonylureas in Patients With Type 2 Diabetes. JAMA Intern Med . 2021 Jun 28;e212488.

Fig. 3 Position of SgIT2is in international guidelines



Which one?

Along side of life style modification (calorie restriction and increasing physical activity):

- 1. Start with Metformin 500 mg BD then add Empagliflozin 10 mg/day or change to Metformin/Empagliflozin (500/5) BD
- 2. Start with Empagliflozin Plus (500/5) BD then increase to Empagliflozin Plus (1000/5) BD
- 3. Start with Empagliflozin plus (500/5) BD then add Sitagliptin 50 mg/day
- 4. Start with Metformin 500 mg BD and Liraglutide
- 5. Start with Metformin 500 mg BD and Liraglutide then add Empagliflozin 10 mg/day
- 6. Start with Glibenclamide 5 mg/day
- 7. Start with Gliclazide MR 30 mg/day then increase the dose or add Metformin
- 8. Other options?



to



Together for a healthy future

team

No. 58, 8th St., Kooye Nasr (Gisha St.), Tehran, IR Iran, Postal Code: 1446863914 Telefax: +98 (21) 41637000

H3C

H3CO

ÓH

www.actoverco.com



Together for a healthy future